Prof Mhairi Copland speaks with ecancertv at ASH 2016 from the DESTINY study, a UK assessment of safely reducing dosage of tyrosine kinase therapy for patients with a deep molecular response.
She describes the rationale behind the destiny study, based on TKIs most commonly prescribed to treat CML, and considers the patient benefits associated with dose reduction, including better outlooks on adverse events and affordability.
